COVID-19 update, 7 June 2025: India's active case count nears 6,000 with 391 new infections; Kerala, Delhi lead surge
India has reported 391 Covid-19 cases in the past 24 hours, according to the data. This is a drop from the 498 cases that the country recorded on Friday. The number of Covid-19 patients who have been discharged over the past 24 hours were recorded at 760. This is a decrease from the 764 recoveries recorded on Friday.
As many as four people died due to Covid-related issues over the past day, according to the data. The deaths were reported from Kerala, Madhya Pradesh, Tamil Nadu and Maharashtra.
In Maharashtra, a pregnant 45-year-old woman died in the hospital after she started having intrapartum seizures after which she became intubated. She later tested Covid-19 positive. Another 59-year-old man in Kerala with lung cancer passed away. The two other patients who died were over 60 years of age and had comorbidities. Kerala recorded most number of Covid-19 cases on Saturday at 127, while one person died in the state. This was followed by Gujarat and Delhi.
Gujarat recorded 183 new coronavirus positive cases on Saturday, taking the active count in the state to 822, the health department said. However, no death was reported in the past 24 hours. All the cases which are emerging in Gujarat are of JN.1, LF.7, LF.7.9 and XFG variants of the Omicron family, which causes mild fever and cough, the health department said.
Maharashtra on Saturday reported 86 new cases, taking the total count since January to 1,362. Of these new cases, 31 were detected in Pune city and two in its rural parts and 28 tested positive in Mumbai, an official statement said. Uttarakhand recorded four new coronavirus positive cases on Saturday. Seven people have tested positive for Covid-19 in Dehradun on Friday, with the health department tracking down those who came in contact with them.
Odisha Education Minister Nityananda Gond said the government is cautious about Covid-19 and that teachers should be trained to prevent Covid-19 infection when exposure to the virus cannot be avoided.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
5 hours ago
- Hindustan Times
SC lifts HC stay, paves way for admission process to restart in MP's paramedical courses
New Delhi, The Supreme Court on Friday paved the way for restarting the admission process in paramedical courses for the academic years 2023–24 and 2024–25 in Madhya Pradesh. SC lifts HC stay, paves way for admission process to restart in MP's paramedical courses On July 16, a division bench of the Madhya Pradesh High Court at Jabalpur stayed the ongoing recognition and admission process for paramedical courses for 2023–24 and 2024–25 by taking note of a plea filed by the law students' association. The MP High Court had stayed the admission process in paramedical courses after taking note of a plea filed by the law students' association. A top court bench comprising Chief Justice B R Gavai and Justice K Vinod Chandran was apprised by senior advocate Mukul Rohatgi, appearing for the registrar of Madhya Pradesh Paramedical Council, that such a drastic order was passed by the high court on a petition filed by some law students having no locus in the matter. The senior lawyer referred to COVID-19 pandemic and said that certain paramedical courses in the states could not begin on time due to the pandemic. He said the registrar of the Paramedical Council grants recognition to institutions and regulates the admission process and the impugned order of the high court has brought everything to a standstill. "How can law students file such a petition?" the CJI asked, and stayed the high court order. The CJI also issued notices to the state government and others on the plea of the Paramedical Council. The high court stay order came following a move to permit 166 paramedical institutions to begin courses for the 2023–24 academic year, despite granting recognition to these institutions only in 2025. The high court found the timeline "illogical" and questioned how institutions could start academic sessions for 2023–24 in the year 2025 when they did not even exist at the time the courses were supposed to commence. It examined the order of July 14 of the Paramedical Council granting permission to 166 institutions to offer courses for 2023–24. However, the high court pointed out that the courses were originally scheduled to run from November 2023 to October 2024 and that the last date for institutions to apply for recognition was December 31, 2023. The bench expressed strong disapproval of the retrospective recognition, stating, "It belies all logic, sensibility and questions the sanity of a reasonable man how these institutions could be allowed to start the course for the year 2023-24 in the year 2025." This article was generated from an automated news agency feed without modifications to text.
The Hindu
9 hours ago
- The Hindu
US vaccination rates for measles, other diseases drop further, government data says
Vaccination rates for several diseases including measles, diphtheria and polio decreased among U.S. kindergartners in the 2024-25 school year from the year before, according to federal data posted on Thursday. The U.S. Centers for Disease Control and Prevention released the new figures at a time when the country faces a growing measles outbreak, with confirmed cases this month reaching the highest level since the disease was declared eliminated from the country in 2000. Secretary of Health and Human Services Robert F. Kennedy Jr. has long questioned the safety of vaccines, contrary to scientific evidence, and he has also suggested a link between vaccines and autism. The CDC data show vaccination rates have steadily trended down since the COVID-19 pandemic. For the measles, mumps and rubella vaccine, coverage went from 95.2% in the 2019-2020 school year to 92.7% last year, before landing at 92.5% in 2024-2025. In Texas, the epicenter of the recent outbreak, MMR coverage has fallen to 93.2% from 96.9% in 2019. Most people are protected from measles through herd immunity when more than 95% of people in the community are vaccinated, the CDC website says. An HHS spokesperson said the data released on Thursday showed a 'majority' of children continue to get routine childhood immunizations, and that vaccination remains the most effective way to protect children from measles and whooping cough. 'The decision to vaccinate is a personal one,' the spokesperson said. 'Parents should consult their healthcare providers on options for their families.' In addition, exemptions from one or more vaccines increased to 3.6% in 2024-2025 from 3.3% the year before, the CDC website said. Exemptions, which can be granted on medical or religious grounds, increased in 36 states and DC, with 17 states reporting exemptions exceeding 5 percent, it said.
NDTV
9 hours ago
- NDTV
US FDA Vaccine Chief Vinay Prasad Leaves Agency 3 Months After Appointment
Washington: The Food and Drug Administration's polarizing vaccine chief is leaving the agency after a brief tenure that drew the ire of biotech executives, patient groups and conservative allies of President Donald Trump. Dr. Vinay Prasad 'did not want to be a distraction' and was stepping down from his role as the FDA's top vaccine regulator 'to spend more time with his family,' a spokesperson for the Department of Health and Human Services said in a statement late Tuesday. Two people familiar with the situation told The Associated Press that Prasad was ousted following several recent controversies. They spoke on condition of anonymity to discuss internal personnel matters. Prasad did not immediately respond to requests for comment Wednesday morning. FDA's drug center director, Dr. George Tidmarsh, will take over Prasad's job in an acting role, according to an agency email shared with the AP. Tidmarsh started at the FDA last week after a decades-long career as a pharmaceutical executive and adjunct professor. Prasad joined the FDA in May from the University of California San Francisco, where he frequently criticized the FDA's approach to drug approvals and COVID-19 vaccines. His contrarian approach appeared to match that of his boss FDA Commissioner Marty Makary, who repeatedly praised Prasad's work and intellect. But in recent weeks Prasad became a target of right-wing activists, including Laura Loomer, who flagged Prasad's past statements criticizing Trump and praising liberal independent Senator Bernie Sanders. 'How did this Trump-hating Bernie Bro get into the Trump admin???' Loomer posted on X last week. Trump previously fired several national security officials a day after Loomer raised concerns about their loyalty. Prasad also attracted scrutiny for his handling of a recent safety issue surrounding the only approved gene therapy for Duchenne's muscular dystrophy. Under his direction, shipments of the therapy were briefly halted after a series of patient deaths, then resumed late Monday following vocal pushback from families of boys with the fatal muscle-wasting disorder. Prasad has long been skeptical of the therapy and other muscular dystrophy drugs sold by the drugmaker, Sarepta Therapeutics. As an academic, Prasad gained prominence by attacking the FDA for being too lenient in its standards for approving cancer drugs and other new therapies. That approach is at odds with Trump's Republican supporters, who generally favor speedier approvals and unfettered access to experimental treatments. During Trump's first term he signed the ' Right to Try ' law, a largely symbolic piece of legislation that won popular support from conservatives seeking to give terminal patients expanded access to unproven drugs. Prasad's decision to pause Sarepta's therapy was criticized last week by a columnist and the editorial board of The Wall Street Journal. Separately, Prasad's division issued three rejection letters this month to small biotech firms seeking approval for new gene therapies. Those drugs have been vigorously embraced by many of the anti-abortion groups in Trump's base for their potential to address intractable diseases that sometimes lead parents to terminate pregnancies. Prasad's predecessor in at FDA, Dr. Peter Marks, oversaw a dramatic rise in approvals for new gene therapies, which aim to treat or prevent disease by replacing or modifying a portion of patients' genetic code. Prasad has been an outspoken critic of Marks' leadership at FDA, which included overseeing the approval of the first COVID vaccines and therapies.
